Article thumbnail

'Rac'-ing upstream to treat rheumatoid arthritis

By Gary S Firestein


Signal transduction pathways regulate the production and function of many cytokines implicated in immune-mediated diseases. Targeting these enzymes with small molecule inhibitors represents a fertile field for the treatment of rheumatoid arthritis. Recent successes with compounds that block upstream kinases suggest that proximal members of the signaling cascades, such as Rac and other Rho family enzymes, might have therapeutic potential. Balancing efficacy and toxicity, however, remains a significant challenge that will require careful evaluation

Topics: Editorial
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. Firestein GS: ‘Go upstream, young man’: lessons learned from the p38 saga. Ann Rheum Dis 2010, 69(Suppl 1):i77-i82.
  2. (2002). Firestein GS: Regulation of joint destruction and infl ammation by p53 in collagen-induced arthritis.
  3. (2010). GS: Kinetic analysis of synovial signaling and gene expression in animal models of arthritis. Ann Rheum Dis 2010. [Epub ahead of print]
  4. (2010). Hordijk PL, Tak PP: A Rac1 inhibitory peptide suppresses antibody production and paw swelling in the murine collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther
  5. (2008). Ridley AJ: Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol
  6. (2009). Spencer-Green GT: Effi cacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum
  7. (2008). Vicente-Gonzales AV, Grossbard E: Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum
  8. (2009). Zwillich SH: The safety and effi cacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum